Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Diagnosis Group; Systemic Therapy Group

doi:10.1016/j.jfma.2020.10.031

Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Diagnosis Group, Systemic Therapy Group

Research output: Contribution to journal › Journal Article › peer-review

76 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid–enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.

Original language	English
Pages (from-to)	1051-1060
Number of pages	10
Journal	Journal of the Formosan Medical Association
Volume	120
Issue number	4
DOIs	https://doi.org/10.1016/j.jfma.2020.10.031
State	Published - 04 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020

Keywords

Diagnosis
Guideline
Hepatocellular carcinoma
Surveillance
Systemic treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jfma.2020.10.031

Fingerprint

Dive into the research topics of 'Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan'. Together they form a unique fingerprint.

Cite this

@article{19f50c86209b4fa18ca716ce84223a03,

title = "Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan",

abstract = "Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid–enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.",

keywords = "Diagnosis, Guideline, Hepatocellular carcinoma, Surveillance, Systemic treatment",

author = "{Diagnosis Group} and {Systemic Therapy Group} and Shao, {Yu Yun} and Wang, {Shen Yung} and Lin, {Shi Ming} and Chen, {Kuan Yang} and Tseng, {Jeng Hwei} and Ho, {Ming Chih} and Lee, {Rheun Chuan} and Liang, {Po Chin} and Liao, {Li Ying} and Huang, {Kai Wen} and Hu, {Jui Ting} and Liang, {Ja Der} and Kee, {Kwong Ming} and Lin, {Chih Lin} and Wang, {Chung Kwe} and Lu, {Sheng Nan} and Wang, {Jing Houng} and Lee, {Wei Chen} and Chen, {Chien Hung} and Liu, {Chun Jen} and Huang, {Yi Hsiang} and Wang, {Chia Chi} and Wang, {Tsang En} and Chuang, {Po Heng} and Dai, {Chia Yen} and Chiun Hsu and Chen, {San Chi} and Hsieh, {Chia Hsun}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2021",

month = apr,

doi = "10.1016/j.jfma.2020.10.031",

language = "英语",

volume = "120",

pages = "1051--1060",

journal = "Journal of the Formosan Medical Association",

issn = "0929-6646",

publisher = "Elsevier B.V.",

number = "4",

}

Diagnosis Group & Systemic Therapy Group 2021, 'Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan', Journal of the Formosan Medical Association, vol. 120, no. 4, pp. 1051-1060. https://doi.org/10.1016/j.jfma.2020.10.031

Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. / Diagnosis Group; Systemic Therapy Group.
In: Journal of the Formosan Medical Association, Vol. 120, No. 4, 04.2021, p. 1051-1060.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Management consensus guideline for hepatocellular carcinoma

T2 - 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

AU - Diagnosis Group

AU - Systemic Therapy Group

AU - Shao, Yu Yun

AU - Wang, Shen Yung

AU - Lin, Shi Ming

AU - Chen, Kuan Yang

AU - Tseng, Jeng Hwei

AU - Ho, Ming Chih

AU - Lee, Rheun Chuan

AU - Liang, Po Chin

AU - Liao, Li Ying

AU - Huang, Kai Wen

AU - Hu, Jui Ting

AU - Liang, Ja Der

AU - Kee, Kwong Ming

AU - Lin, Chih Lin

AU - Wang, Chung Kwe

AU - Lu, Sheng Nan

AU - Wang, Jing Houng

AU - Lee, Wei Chen

AU - Chen, Chien Hung

AU - Liu, Chun Jen

AU - Huang, Yi Hsiang

AU - Wang, Chia Chi

AU - Wang, Tsang En

AU - Chuang, Po Heng

AU - Dai, Chia Yen

AU - Hsu, Chiun

AU - Chen, San Chi

AU - Hsieh, Chia Hsun

PY - 2021/4

Y1 - 2021/4

N2 - Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid–enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.

AB - Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid–enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.

KW - Diagnosis

KW - Guideline

KW - Hepatocellular carcinoma

KW - Surveillance

KW - Systemic treatment

UR - http://www.scopus.com/inward/record.url?scp=85096382417&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2020.10.031

DO - 10.1016/j.jfma.2020.10.031

M3 - 文章

C2 - 33199101

AN - SCOPUS:85096382417

SN - 0929-6646

VL - 120

SP - 1051

EP - 1060

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

IS - 4

ER -

Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this